This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

NICE guidance - Secukinumab for treating moderate to severe plaque psoriasis in children and young people

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

NICE guidance - Secukinumab for treating moderate to severe plaque psoriasis in children and young people

NICE state (1):

  • Secukinumab is recommended as an option for treating plaque psoriasis in children and young people aged 6 to 17 years, only if:
    • the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and
    • the disease has not responded to other systemic treatments, including ciclosporin, methotrexate and phototherapy, or these options are contraindicated or not tolerated and
    • the company provides the drug according to the commercial arrangement
  • stop secukinumab treatment at 12 weeks if the psoriasis has not responded adequately. An adequate response is defined as a 75% reduction in the PASI score (PASI 75) from when treatment started
  • choose the least expensive treatment if patients (or their parents or carers) and their clinicians consider secukinumab to be one of a range of suitable treatments. Take into account availability of biosimilar products, administration costs, dosage, price per dose and commercial arrangements
  • take into account how skin colour could affect the PASI score and make any appropriate clinical adjustments

Secukinumab for treating moderate to severe plaque psoriasis in children and young people

  • is a human monoclonal antibody targeting IL-17A
  • and blocks its interaction with the IL-17 receptor
  • inhibition of the downstream effects of this proinflammatory cytokine thereby interferes with key psoriasis disease pathways while promoting normalization of immune function and skin histology
    • psoriasis is a systemic inflammatory disease associated with numerous comorbidities and a profound impact on patients' quality of life
    • evidence supports a fundamental role of the T-helper-17 (TH-17) pathway and its related interleukin-17 (IL-17) cytokine
    • identification of T-helper-17 (Th17) cells in psoriatic lesional skin implicated this T-cell population as a key contributor to the proinflammatory state of psoriasis
    • IL-17A receptors are expressed on the surface of keratinocytes, making these cells the primary target in psoriasis
      • upon IL-17A binding, there is increased keratinocyte expression of numerous chemokines (i.e. CCL20, CXCL1, and CXCL8), which play a role in recruiting inflammatory cells to lesional skin and stimulating the innate immune system
        • this complex interaction ultimately contributes to epidermal hyperproliferation and skin barrier dysfunction, important factors in psoriasis pathogenesis
        • effects of IL-17A are augmented by other inflammatory mediators, particularly, TNF-alpha
  • recommended dosing for secukinumab differs for psoriasis as compared to psoriatic arthritis and ankylosing spondylitis
  • Secukinumab - cautions and contraindications (2)
    • is contraindicated in patients with a hypersensitivity reaction to secukinumab or to any of its excipients
    • recommended to evaluate patients for tuberculosis infection prior to initiating treatment with secukinumab
    • should be avoided in patients with preexisting inflammatory bowel disease (IBD)
    • may increase the risk for infection, and live vaccines should not be given to patients treated with secukinumab


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.


Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.